Sinovac Biotech Ltd. (SVA) is a leading biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccines that protect against various infectious diseases. The company is headquartered in Beijing, China, and is listed on the NASDAQ. Since its establishment in 2001, Sinovac has focused on improving global health by providing accessible and affordable vaccines.
Sinovac has achieved significant success in developing vaccines for several crucial diseases. It takes a multifaceted approach to vaccine development using both proprietary and in-licensed technologies. A considerable part of the company's portfolio is dedicated to pediatric vaccines, including those that protect against Hepatitis B, Influenza, and mumps. However, the company’s scope extends far beyond pediatric vaccines, and it is actively involved in creating effective solutions for adults and elderly populations as well.
Sinovac has made headlines for its CoronaVac vaccine, an inactivated COVID-19 vaccine. Its development and distribution have made a significant contribution towards the global battle against the COVID-19 pandemic.
The company's prominence in the scientific and medical community has wooed investors worldwide, making the biotech firm a robust presence in the stock market under the symbol SVA. As the company's standing continues to strengthen, Sinovac’s achievements are indicative of its commitment to global health, and its ability to perform and deliver even during challenging times.
Sinovac Biotech continues to invest heavily in research and development, with ongoing trials for vaccines against hand, foot, and mouth disease, seasonal influenza, and avian flu, among others.
Furthermore, Sinovac operates several manufacturing facilities that meet international standards, ensuring the production of safe and effective vaccines. In terms of global reach, Sinovac products are available in over 30 countries, including China, Mexico, Thailand, Turkey, and the Philippines.
Underlying Sinovac's growth is its collaboration with other organizations and its commitment to social responsibility. The company partners with governments, non-government organizations, and research institutions to ensure that its vaccines are accessible to those in need.
Through its influential work on infectious diseases, Sinovac Biotech Ltd. exemplifies a commitment to improvement in global public health, reflecting the significant role the company continues to play in the biotech industry. The company's persistent innovation and expansive portfolio of vaccines undoubtedly mark Sinovac as a key player in responding to global health crises, now and in the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Indonesia has administered over 100 million doses of the COVID-19 vaccine, a milestone attributed to collaboration among various parties and high public awareness. A health worker was photographed preparing a Sinovac Biotech Ltd. vaccine during a mass vaccination event in Bogor, West Java, on September 20, 2021. The picture highlights the country's vaccination efforts.
This article describes a technician preparing the H1N1 flu virus for vaccine production at a lab in Wuhan, China, back in June 2009. Chinese vaccine maker Sinovac Biotech Ltd aimed for clinical trials by July 2009, following the World Health Organization's pandemic declaration. The process involved growing the virus in chicken eggs to develop a vaccine.
This article describes a technician placing eggs into an incubator in a Wuhan lab to produce H1N1 flu vaccines. Chinese vaccine maker Sinovac Biotech Ltd aimed for its first clinical trial by the end of July 2009, following the World Health Organization's declaration of a pandemic. Thousands of chicken eggs were prepared to grow the H1N1 virus for vaccine production.
Sinovac Biotech Ltd. (SVA) reported a net loss per share of -$0.84 for the First Half 2026, with a total revenue of $147.1 million, marking a 12.9% increase year-over-year. The company's overseas revenue grew significantly by 82.3%, and its Varicella vaccine contributed $48.5 million in revenue, up 62.4%. SVA recorded a net loss of $91.4 million for the quarter.
Sinovac Biotech Ltd. (SVA) reported its First Half 2026 financial results, showing a basic and diluted net loss per share of -$0.84. The company generated $147.1 million in revenue for the quarter, marking a 12.9% increase year-over-year. Overseas revenue saw significant growth of 82.3%, with the varicella vaccine contributing $48.5 million, up 62.4% year-over-year, despite a net loss of $91.4 million for the quarter.
Chinese vaccine maker Sinovac Biotech has received regulatory approval for China's first serum-free rabies vaccine. This vaccine uses an animal component-free manufacturing process and supports a shortened four-dose vaccination schedule recommended by the World Health Organization. It is approved for both the conventional five-dose regimen and the WHO-recommended four-dose schedule for post-exposure prophylaxis.